CIK 0001478320 · Large accelerated filer
Adaptive Biotechnologies Corp
Sign in to watch- Ticker
- ADPT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- WA
- Entity type
- operating
- EIN
- 270907024
- Phone
- 206-659-0067
- Business address
- 1165 EASTLAKE AVE E, SEATTLE, WA, 98109
- Former names
- Adaptive TCR Corp
- 4 Grant or award SVP and General Counsel acquired 13,736 shares (grant or award)
- 4 Grant or award SVP, Diagnostics, immunoSEQ Dx acquired 9,158 shares (grant or award)
- 4 Grant or award EVP & Chief Operating Officer acquired 20,604 shares (grant or award)
- 4 Grant or award Chief Business Development Off acquired 22,894 shares (grant or award)
- 4 Grant or award Chief People Officer acquired 20,604 shares (grant or award)
- 4 Grant or award CEO and Chairman acquired 68,681 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 20,604 shares (grant or award)
- 4 Grant or award SVP, Diagnostics, clonoSEQ acquired 9,158 shares (grant or award)
- 8-K Event Executive or director change
- 4 Open-market sale Chief Business Development Off sold 416 shares at $61.20 ($25,459)
- 4 Open-market sale President sold 15,000 shares at an average $58.32 ($874,743)
- 4 Open-market sale Director sold 20,000 shares at $57.80 ($1,156,000)
- 4 Open-market sale Chief Business Development Off sold 6,771 shares at an average $57.62 ($390,143)
- 8-K Event Regulation FD disclosure · Other events
- 4 Open-market sale President sold 15,000 shares at $56.23 ($843,450)
- 4 Open-market sale SVP and General Counsel sold 2,812 shares at an average $55.53 ($156,138)
- 4 Open-market sale President sold 29,675 shares at an average $56.99 ($1,691,056)
- 4 Open-market sale President sold 30,000 shares at an average $57.58 ($1,727,410)
- 10-K Report Annual Report
- 8-K Event Results of operations
Page 25 of 42 · 837 filings